Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

Despite promising data, Sana's CEO provides a sober timeline for their type 1 diabetes cell therapy. While clinical proof-of-concept ("does it work?") is expected within 12-18 months, even a "super optimistic" commercial launch would not happen until later this decade. This highlights the lengthy process of scaling manufacturing and navigating regulatory pathways.

The founder of Project Insulin reveals it took five and a half years of work—primarily fundraising and planning—just to sign the contract with a CDMO to begin drug development. This highlights the immense, often invisible, runway required before the 'real' scientific work starts, demanding extreme patience and long-term commitment.

The greatest barrier to biomedical advancement is the exorbitant cost ($25M+) and time (18+ months) required for the FDA's initial new drug (IND) application. By adopting a faster, notification-based system like Australia's, the U.S. could unlock a wave of innovation, lower costs, and prevent the industry from offshoring to China.

Contrary to the perception that drug development is all about human trials, the first five years of the typical decade-long journey are dedicated to rigorous preclinical work. This foundational stage involves chemistry and non-human testing before a molecule ever reaches a patient.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

Drug development can take a decade, a timeframe that misaligns with typical investor horizons and employee careers. Success requires navigating fluctuating capital market cycles and implementing strategies to retain key scientific talent for the long haul.

The primary bottleneck in U.S. clinical trials is not the FDA's 30-day IND approval process, but the slow, expensive 'nuts and bolts' of site activation. This includes redundant budget negotiations, contract formats, and separate scientific and IRB reviews for the same protocol across multiple institutions.

Unlike for-profit ventures driven by rapid ROI, a non-profit biotech's timeline is dictated by maximizing the chances of success. The founder is comfortable if it takes five years just to complete pre-IND submissions, as the primary goal is ensuring the drug gets approved by the FDA, not rushing to market for investors.